Close Menu

NEW YORK (GenomeWeb) – Washington University in St. Louis has partnered with ArcherDX to assess minimum residual disease in pediatric acute myeloid leukemia patients.

Researchers plan to use ArcherDX's sequencing technology to analyze 870 patients who are part of a Children's Oncology Group clinical trial that is analyzing different treatment regimens for pediatric AML patients with Down syndrome based on how they respond to an initial induction therapy.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Sponsored by
Thermo Fisher Scientific

This webinar will review how liquid biopsy can be considered as an alternative and non-invasive method to tissue biopsy for cancer molecular characterization.

Sponsored by

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.